(WRB) W. R. Berkley - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0844231029
Stock: Commercial Insurance, Reinsurance, Specialty Lines
Total Rating 54
Risk 84
Buy Signal -0.07
| Risk 5d forecast | |
|---|---|
| Volatility | 22.5% |
| Relative Tail Risk | -2.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.56 |
| Alpha | 9.18 |
| Character TTM | |
|---|---|
| Beta | 0.122 |
| Beta Downside | 0.288 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.10% |
| CAGR/Max DD | 1.45 |
EPS (Earnings per Share)
Revenue
Description: WRB W. R. Berkley March 05, 2026
W. R. Berkley Corporation (WRB) is an insurance holding company operating globally. It specializes in commercial lines, a segment of the insurance industry focused on covering business risks.
The company has two primary segments: Insurance and Reinsurance & Monoline Excess. The Insurance segment underwrites various commercial insurance products, including excess and surplus lines, admitted lines, and specialty personal lines. This broad offering is typical for large commercial insurers, which often diversify across multiple risk categories to manage exposure.
The Reinsurance & Monoline Excess segment provides treaty and facultative reinsurance solutions. Reinsurance is a common practice in the insurance industry where insurers transfer portions of their risk portfolios to other insurers to reduce their own potential losses from large claims.
Further research on ValueRay can provide more in-depth analysis of WRBs financial performance and market position.
Headlines to watch out for
- Commercial insurance pricing dictates underwriting profitability
- Investment portfolio performance impacts net income
- Catastrophic events increase claims and reduce reserves
- Regulatory changes influence capital requirements and product offerings
- Competition affects premium volume and market share
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.02 > 1.0 |
| NWC/Revenue: 70.38% < 20% (prev 230.3%; Δ -159.9% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.60b > Net Income 1.78b |
| Net Debt (299.8m) to EBITDA (2.37b): 0.13 < 3 |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (399.1m) vs 12m ago -0.44% < -2% |
| Gross Margin: 19.81% > 18% (prev 0.23%; Δ 1958 % > 0.5%) |
| Asset Turnover: 34.75% > 50% (prev 33.62%; Δ 1.13% > 0%) |
| Interest Coverage Ratio: 14.22 > 6 (EBITDA TTM 2.37b / Interest Expense TTM 126.9m) |
Altman Z'' 3.21
| A: 0.23 (Total Current Assets 36.89b - Total Current Liabilities 26.54b) / Total Assets 44.07b |
| B: 0.30 (Retained Earnings 13.34b / Total Assets 44.07b) |
| C: 0.04 (EBIT TTM 1.80b / Avg Total Assets 42.32b) |
| D: 0.38 (Book Value of Equity 13.05b / Total Liabilities 34.36b) |
| Altman-Z'' Score: 3.21 = A |
Beneish M -3.04
| DSRI: 0.97 (Receivables 7.23b/6.92b, Revenue 14.71b/13.64b) |
| GMI: 1.16 (GM 19.81% / 22.89%) |
| AQI: 0.76 (AQ_t 0.15 / AQ_t-1 0.20) |
| SGI: 1.08 (Revenue 14.71b / 13.64b) |
| TATA: -0.04 (NI 1.78b - CFO 3.60b) / TA 44.07b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of WRB shares?
As of March 09, 2026, the stock is trading at USD 69.92 with a total of 1,677,123 shares traded.
Over the past week, the price has changed by -4.53%, over one month by +1.10%, over three months by +6.78% and over the past year by +14.02%.
Over the past week, the price has changed by -4.53%, over one month by +1.10%, over three months by +6.78% and over the past year by +14.02%.
Is WRB a buy, sell or hold?
W. R. Berkley has received a consensus analysts rating of 3.56.
Therefor, it is recommend to hold WRB.
- StrongBuy: 5
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the WRB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.3 | -2.3% |
| Analysts Target Price | 68.3 | -2.3% |
WRB Fundamental Data Overview March 07, 2026
P/E Trailing = 15.7124
P/E Forward = 15.0602
P/S = 1.8066
P/B = 2.7173
P/EG = 10.7617
Revenue TTM = 14.71b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 2.37b USD
Long Term Debt = 2.84b USD (from longTermDebt, last quarter)
Short Term Debt = 61.5m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 299.8m USD (from netDebt column, last quarter)
Enterprise Value = 632.7m USD (26.57b + Debt 2.84b - CCE 28.78b)
Interest Coverage Ratio = 14.22 (Ebit TTM 1.80b / Interest Expense TTM 126.9m)
EV/FCF = 0.18x (Enterprise Value 632.7m / FCF TTM 3.43b)
FCF Yield = 542.1% (FCF TTM 3.43b / Enterprise Value 632.7m)
FCF Margin = 23.32% (FCF TTM 3.43b / Revenue TTM 14.71b)
Net Margin = 12.10% (Net Income TTM 1.78b / Revenue TTM 14.71b)
Gross Margin = 19.81% ((Revenue TTM 14.71b - Cost of Revenue TTM 11.79b) / Revenue TTM)
Gross Margin QoQ = 20.58% (prev 18.23%)
Tobins Q-Ratio = 0.01 (Enterprise Value 632.7m / Total Assets 44.07b)
Interest Expense / Debt = 1.11% (Interest Expense 31.6m / Debt 2.84b)
Taxrate = 20.49% (117.2m / 572.0m)
NOPAT = 1.43b (EBIT 1.80b * (1 - 20.49%))
Current Ratio = 1.39 (Total Current Assets 36.89b / Total Current Liabilities 26.54b)
Debt / Equity = 0.29 (Debt 2.84b / totalStockholderEquity, last quarter 9.70b)
Debt / EBITDA = 0.13 (Net Debt 299.8m / EBITDA 2.37b)
Debt / FCF = 0.09 (Net Debt 299.8m / FCF TTM 3.43b)
Total Stockholder Equity = 9.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 1.78b / Total Assets 44.07b)
RoE = 18.88% (Net Income TTM 1.78b / Total Stockholder Equity 9.43b)
RoCE = 14.71% (EBIT 1.80b / Capital Employed (Equity 9.43b + L.T.Debt 2.84b))
RoIC = 11.69% (NOPAT 1.43b / Invested Capital 12.27b)
WACC = 5.83% (E(26.57b)/V(29.41b) * Re(6.36%) + D(2.84b)/V(29.41b) * Rd(1.11%) * (1-Tc(0.20)))
Discount Rate = 6.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF] Terminal Value 87.44% ; FCFF base≈3.49b ; Y1≈3.93b ; Y5≈5.28b
[DCF] Fair Price = 414.4 (EV 155.50b - Net Debt 299.8m = Equity 155.21b / Shares 374.5m; r=5.90% [WACC]; 5y FCF grow 14.72% → 2.90% )
EPS Correlation: -8.08 | EPS CAGR: 0.72% | SUE: -0.14 | # QB: 0
Revenue Correlation: 94.48 | Revenue CAGR: 6.71% | SUE: 3.11 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.10 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=4.57 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=-11 | Growth EPS=+5.5% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=4.85 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=-8 | Growth EPS=+6.1% | Growth Revenue=+4.7%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.4%)
[Growth] Growth Spread = +2.4% (Analyst 4.0% - Implied 1.6%)
P/E Forward = 15.0602
P/S = 1.8066
P/B = 2.7173
P/EG = 10.7617
Revenue TTM = 14.71b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 2.37b USD
Long Term Debt = 2.84b USD (from longTermDebt, last quarter)
Short Term Debt = 61.5m USD (from shortTermDebt, last quarter)
Debt = 2.84b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 299.8m USD (from netDebt column, last quarter)
Enterprise Value = 632.7m USD (26.57b + Debt 2.84b - CCE 28.78b)
Interest Coverage Ratio = 14.22 (Ebit TTM 1.80b / Interest Expense TTM 126.9m)
EV/FCF = 0.18x (Enterprise Value 632.7m / FCF TTM 3.43b)
FCF Yield = 542.1% (FCF TTM 3.43b / Enterprise Value 632.7m)
FCF Margin = 23.32% (FCF TTM 3.43b / Revenue TTM 14.71b)
Net Margin = 12.10% (Net Income TTM 1.78b / Revenue TTM 14.71b)
Gross Margin = 19.81% ((Revenue TTM 14.71b - Cost of Revenue TTM 11.79b) / Revenue TTM)
Gross Margin QoQ = 20.58% (prev 18.23%)
Tobins Q-Ratio = 0.01 (Enterprise Value 632.7m / Total Assets 44.07b)
Interest Expense / Debt = 1.11% (Interest Expense 31.6m / Debt 2.84b)
Taxrate = 20.49% (117.2m / 572.0m)
NOPAT = 1.43b (EBIT 1.80b * (1 - 20.49%))
Current Ratio = 1.39 (Total Current Assets 36.89b / Total Current Liabilities 26.54b)
Debt / Equity = 0.29 (Debt 2.84b / totalStockholderEquity, last quarter 9.70b)
Debt / EBITDA = 0.13 (Net Debt 299.8m / EBITDA 2.37b)
Debt / FCF = 0.09 (Net Debt 299.8m / FCF TTM 3.43b)
Total Stockholder Equity = 9.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 1.78b / Total Assets 44.07b)
RoE = 18.88% (Net Income TTM 1.78b / Total Stockholder Equity 9.43b)
RoCE = 14.71% (EBIT 1.80b / Capital Employed (Equity 9.43b + L.T.Debt 2.84b))
RoIC = 11.69% (NOPAT 1.43b / Invested Capital 12.27b)
WACC = 5.83% (E(26.57b)/V(29.41b) * Re(6.36%) + D(2.84b)/V(29.41b) * Rd(1.11%) * (1-Tc(0.20)))
Discount Rate = 6.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF] Terminal Value 87.44% ; FCFF base≈3.49b ; Y1≈3.93b ; Y5≈5.28b
[DCF] Fair Price = 414.4 (EV 155.50b - Net Debt 299.8m = Equity 155.21b / Shares 374.5m; r=5.90% [WACC]; 5y FCF grow 14.72% → 2.90% )
EPS Correlation: -8.08 | EPS CAGR: 0.72% | SUE: -0.14 | # QB: 0
Revenue Correlation: 94.48 | Revenue CAGR: 6.71% | SUE: 3.11 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.10 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=4.57 | Chg7d=-0.008 | Chg30d=-0.008 | Revisions Net=-11 | Growth EPS=+5.5% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=4.85 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=-8 | Growth EPS=+6.1% | Growth Revenue=+4.7%
[Analyst] Revisions Ratio: -0.80 (1 Up / 9 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.4%)
[Growth] Growth Spread = +2.4% (Analyst 4.0% - Implied 1.6%)